Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NBSE
- Price
- -
- Stock movement up
- +- (%)
- Company name
- NeuBase Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.42M
- Ent value
- -1.67M
- Price/Sales
- -
- Price/Book
- 0.16
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -37.19%
- 1 year return
- 90.24%
- 3 year return
- -57.74%
- 5 year return
- -33.52%
- 10 year return
- -46.00%
Last updated: 2024-12-17
DIVIDENDS
NBSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.16 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.75M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 12.57M |
| Net receivables | 0.00 |
| Total current assets | 13.35M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 5.36M |
| Total assets | 18.62M |
| Accounts payable | 258.64K |
| Short/Current long term debt | 5.34M |
| Total current liabilities | 4.65M |
| Total liabilities | 9.48M |
| Shareholder's equity | 9.14M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| NBSE | S&P500 | |
| Current price drop from All-time high | -99.90% | -0.36% |
| Highest price drop | -99.97% | -19.00% |
| Date of highest drop | 26 Apr 2023 | 8 Apr 2025 |
| Avg drop from high | -86.27% | -2.76% |
| Avg time to new high | 110 days | 5 days |
| Max time to new high | 2567 days | 89 days |
COMPANY DETAILS
Marketcap
1.42M
Marketcap category
Small-cap
Description
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Employees
37
Investor relations
-
SEC filings
CEO
Dietrich A. Stephan
Country
USA
City
Pittsburgh
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner